Finoriq research workspace
bioAffinity Technologies, Inc. (BIAF) News
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect. Review BIAF recent headlines, source links, and company news on Finoriq.
Company Snapshot
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
- Company
- bioAffinity Technologies, Inc. (BIAF)
- Ticker
- BIAF
- Market Cap
- $3.3M
- Latest Price
- $0.6884
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.